April 09, 2021 One of the first papers to document the rare thrombotic events seen in Austria and Germany involving a form of thrombocytopenia after inoculation with the vaccine jointly developed by the University of Oxford and AstraZeneca has now been published in the New England Journal of Medicine, accompanied by a brief report confirming similar findings in a Norwegian cohort. Taken together the papers show a clear link between this particular vaccine and the ”clotting abnormalities” that have led countries around the world to pause or revise their plans for the use of the Oxford/AstraZeneca product. Critically, say authors, the reports also point the way for definitive testing with widely available tests that would permit affected patients to be swiftly identified and treated, potentially averting serious thrombotic events.